



# Consultant 1992 Year-End Index



## Index to Major Subjects and Authors, Volume 32, January-December 1992



### MAJOR SUBJECTS:

**Aging**, and hypertension, clinical guidelines for management. Applegate WB. 92 Oct 32.  
estrogen replacement therapy. Abrams J. 92 Jun 74.

**Anesthetics**, local, guide to office use. Kramer DL, Sherman SC. 92 Nov 25.

**Arrhythmia**, ventricular, approach to oral therapy. Morganroth J. 92 Mar 113.

**Arthritis, rheumatoid**, proper use of disease-modifying agents. Grisante JM, Wilke WS. 92 Jan 23.

**Asthma**, management, questions physicians often ask. Speir WA, Callahan LA. 92 Mar 67.  
status asthmaticus, early intervention and aggressive management. Harman EM. 92 Jan 54.  
unusual presentations, part 1. Reynolds HY, Maxwell SL. 92 Feb 48.  
unusual presentations, part 2. Reynolds HY, Maxwell SL. 92 Apr 79.

**Burns**, primary care approach to management. Cone JB. 92 May 29.

**Bursitis**, local injection therapy. Heller MB. 92 Feb 74.

**Candidiasis**, superficial and invasive infections. Marzouk JB, Kennedy CD. 92 Dec 71.

**Cardiovascular disorders**  
arrhythmias, ventricular, approach to oral therapy. Morganroth J. 92 Mar 113.  
hyperlipidemia, questions physicians often ask. Jones PH. 92 Nov 73.  
hypertension in blacks. Hildreth C. 92 Feb 109.  
hypertension in renal disease. Mailloux LU. 92 Apr 48.  
hypertension in the elderly. Applegate WB. 92 Oct 32.  
hypertensive crises, treatment for emergencies and urgencies. Ram CVS. 92 Aug 46.  
myocardial ischemia, when to consider angioplasty or CABG for

revascularization. Nair R, Thames MD. 92 May 62.

**Chronic fatigue syndrome**, management, what's practical and what isn't. Bryan CS. 92 Apr 33.

**Dental care**, USPSTF screening recommendations. Motley CP, Linder MM, Pierce PJ, Crump WJ. 92 Nov 33.

### Dermatologic disorders

drug rashes, distinguishing them from other lesions. Rothe MJ. 92 May 38.

pigmented skin lesions, malignant vs benign. Roth ME, Grant-Kels JM. 92 Apr 87.

skin signs of systemic cancer. Wooldridge WE. 92 Feb 31.

**Diabetes mellitus**, and hypertension, therapeutic choices. Pedley C, Bloomfield R. 92 Sep 108.  
nephropathy, preventive measures and therapeutic options. Markell M. 92 Jun 100.

**Diagnosis, oral**, normal vs pathologic findings. Barasch A, Eisenberg E. 92 Jun 33.

**Diarrhea**, infectious, questions physicians often ask. Donta ST. 92 Feb 119.

**Drugs**, antimicrobial options, questions physicians often ask. Prichard JG. 92 Jul 86.

local anesthetics, guide to office use. Kramer DL, Sherman SC. 92 Nov 25.  
rashes, distinguishing them from other lesions. Rothe MJ. 92 May 38.

### Editor's Commentaries

Access to top experts—yours for the asking. Williams CF. 92 May 2.

Preast cancer: organizing the fight at the primary care level. Murphy DP. 92 Oct 3.


Chronic fatigue syndrome. Shahady EJ. 92 Apr 3.

Information you—the doctor—ordered. Williams CF. 92 Nov 3.  
Matching our editorial format to your needs. Williams CF. 92 Jan 2.  
Prepare for the coming flu season. Shahady EJ. 92 Sep 2.

# Consultant 1992 Year-End Index



## Index to Major Subjects and Authors, Volume 32, January-December 1992



### MAJOR SUBJECTS:

**Aging**, and hypertension, clinical guidelines for management. Applegate WB. 92 Oct 32.  
estrogen replacement therapy. Abrams J. 92 Jun 74.

**Anesthetics**, local, guide to office use. Kramer DL, Sherman SC. 92 Nov 25.

**Arrhythmia**, ventricular, approach to oral therapy. Morganroth J. 92 Mar 113.

**Arthritis, rheumatoid**, proper use of disease-modifying agents. Grisante JM, Wilke WS. 92 Jan 23.

**Asthma**, management, questions physicians often ask. Speir WA, Callahan LA. 92 Mar 67.  
status asthmaticus, early intervention and aggressive management. Harman EM. 92 Jan 54.  
unusual presentations, part 1. Reynolds HY, Maxwell SL. 92 Feb 48.  
unusual presentations, part 2. Reynolds HY, Maxwell SL. 92 Apr 79.

**Burns**, primary care approach to management. Cone JB. 92 May 29.

**Bursitis**, local injection therapy. Heller MB. 92 Feb 74.

**Candidiasis**, superficial and invasive infections. Marzouk JB, Kennedy CD. 92 Dec 71.

**Cardiovascular disorders**  
arrhythmias, ventricular, approach to oral therapy. Morganroth J. 92 Mar 113.  
hyperlipidemia, questions physicians often ask. Jones PH. 92 Nov 73.  
hypertension in blacks. Hildreth C. 92 Feb 109.  
hypertension in renal disease. Mailloux LU. 92 Apr 48.  
hypertension in the elderly. Applegate WB. 92 Oct 32.  
hypertensive crises, treatment for emergencies and urgencies. Ram CVS. 92 Aug 46.  
myocardial ischemia, when to consider angioplasty or CABG or

revascularization. Nair R, Thames MD. 92 May 62.

**Chronic fatigue syndrome**, management, what's practical and what isn't. Bryan CS. 92 Apr 33.

**Dental care**, USPSTF screening recommendations. Motley CP, Linder MM, Pierce PJ, Crump WJ. 92 Nov 33.

### Dermatologic disorders

drug rashes, distinguishing them from other lesions. Rothe MJ. 92 May 38.

pigmented skin lesions, malignant vs benign. Roth ME, Grant-Kels JM. 92 Apr 87.

skin signs of systemic cancer. Wooldridge WE. 92 Feb 31.

**Diabetes mellitus**, and hypertension, therapeutic choices. Pedley C, Bloomfield R. 92 Sep 108.  
nephropathy, preventive measures and therapeutic options. Markell M. 92 Jun 100.

**Diagnosis, oral**, normal vs pathologic findings. Barasch A, Eisenberg E. 92 Jun 33.

**Diarrhea**, infectious, questions physicians often ask. Donta ST. 92 Feb 119.

**Drugs**, antimicrobial options, questions physicians often ask. Prichard JG. 92 Jul 86.

local anesthetics, guide to office use. Kramer DL, Sherman SC. 92 Nov 25.  
rashes, distinguishing them from other lesions. Rothe MJ. 92 May 38.

### Editor's Commentaries

Access to top experts—yours for the asking. Williams CF. 92 May 2.

Preast cancer: organizing the fight at the primary care level. Murphy DP. 92 Oct 3.

Chronic fatigue syndrome. Shahady EJ. 92 Apr 3.

Information you—the doctor—ordered. Williams CF. 92 Nov 3.  
Matching our editorial format to your needs. Williams CF. 92 Jan 2.  
Prepare for the coming flu season. Shahady EJ. 92 Sep 2.

**TORADOL<sup>®</sup>™ and TORADOL<sup>®</sup> ORAL**  
(ketorolac tromethamine)

maximum milk concentration observed was 7.3 ng/mL and the maximum milk-to-plasma ratio was 0.037. After one day of dosing (qid), the maximum milk concentration was 7.9 ng/mL and the maximum milk-to-plasma ratio was 0.025. Caution should be exercised when TORADOL<sup>®</sup> ORAL is administered to a nursing woman.

**Pediatric Use**

Safety and efficacy in children have not been established. Therefore, TORADOL is not recommended for use in children.

**Use in the Elderly**

Because ketorolac tromethamine is cleared somewhat more slowly by the elderly (see CLINICAL PHARMACOLOGY section of full prescribing information) who are also more sensitive to the renal effects of NSAIDs (see PRECAUTIONS — Renal Effects), extra caution and reduced dosages (see DOSAGE AND ADMINISTRATION section of full prescribing information) should be used when treating the elderly with TORADOL.

**ADVERSE REACTIONS**

Adverse reaction rates from short-term use of NSAIDs are generally from 1/10 to 1/2 the rates associated with long-term use. This is also true for TORADOL. Adverse reaction rates also may increase with higher doses of TORADOL (see WARNINGS, and DOSAGE AND ADMINISTRATION section of full prescribing information). TORADOL is indicated for short-term use. Physicians using TORADOL should be alert for the usual complications of NSAID treatment, and should be aware that with longer use (exceeding 5 days) of TORADOL, the frequency and severity of adverse reactions may increase. Physicians using TORADOL should be alert to the relative risks associated with dose and dose duration as described in CLINICAL PHARMACOLOGY — Clinical Studies section of full prescribing information. Physicians using TORADOL should be alert for the usual complications of NSAID treatment. The adverse reactions listed below were reported in clinical trials with TORADOL in which patients received up to 20 doses, in 5 days, of TORADOL 30 mg or up to 4 doses a day from long-term studies of TORADOL 10 mg qid. In addition, adverse reactions that were reported from TORADOL postmarketing surveillance are included in "Incidence 1% or Less." **Incidence Greater than 1%** (probably causally related): **Body as a Whole:** EDEMA; **Cardiovascular:** HYPERTENSION; **Dermatologic:** RASH, pruritus; **Gastrointestinal:** NAUSEA (12%), DYSPEPSIA (12%), GASTROINTESTINAL PAIN (13%), constipation, diarrhea, flatulence, gastrointestinal fullness, vomiting, STOMATITIS; **Hemic and Lymphatic:** purpura; **Nervous System:** drowsiness, dizziness, HEADACHE (17%), sweating. Injection site pain was reported by 2% of patients in multidosed studies (vs. 5% for the morphine control group). **Incidence of reported reaction between 3% and 9%.** Those reactions occurring in less than 3% of the patients are unmarked. Reactions reported predominantly from long-term TORADOL studies are CAPITALIZED. **Incidence 1% or Less** (probably causally related): **Body as a Whole:** hypersensitivity reactions such as anaphylaxis<sup>1</sup>, bronchospasm, laryngeal edema, tongue edema, hypotension, and flushing, weight gain, fever; **Cardiovascular:** flushing, palpitation, pallor, hypotension, syncope; **Dermatologic:** Lyell's syndrome, Stevens-Johnson syndrome, exfoliative dermatitis, maculo-papular rash, urticaria; **Gastrointestinal:** peptic ulceration, GI hemorrhage, GI perforation (see WARNINGS and PRECAUTIONS), melena, rectal bleeding, gastritis, eructation, anorexia, increased appetite; **Hemic and Lymphatic:** postoperative wound hemorrhage, rarely requiring blood transfusion (see WARNINGS and PRECAUTIONS), thrombocytopenia, epistaxis, anemia; **Nervous System:** convulsions, vertigo, tremors, abnormal dreams, hallucinations, euphoria; **Respiratory:** dyspnea, asthma, pulmonary edema; **Urogenital:** acute renal failure (see WARNINGS and PRECAUTIONS), flank pain with or without hematuria and/or azotemia, oliguria, nephritis.

<sup>1</sup>Italics denote reactions reported from postmarketing experience. **Other Adverse Events** (causal relationship unknown): **Body as a Whole:** asthenia; **Gastrointestinal:** pancreatitis; **Hemic and Lymphatic:** leukopenia, EOSINOPHILIA; **Nervous System:** paresthesia, depression, insomnia, nervousness, excessive thirst, dry mouth, abnormal thinking, inability to concentrate, hyperkinesia, stupor; **Respiratory:** RHINITIS, COUGH, dyspnea; **Special Senses:** abnormal taste, abnormal vision, blurred vision, tinnitus, HEARING LOSS; **Urogenital:** polyuria, increased urinary frequency.

<sup>2</sup>Reactions occurred under circumstances where the causal relationship to TORADOL treatment has not been clearly established; they are presented as alerting information for physicians. Reactions reported predominantly from long-term TORADOL studies are CAPITALIZED.

See package insert for full prescribing information.

CAUTION: Federal law prohibits dispensing without prescription.

U.S. Patent No. 4,089,969 and others



Syntex Laboratories, Inc.  
Palo Alto, CA 94304  
©1992 Syntex Laboratories, Inc.

April 1992  
02-2435-00-01  
P092152A

**Consultant 1992  
Year-End Index**

Guide to  
Major Subjects  
and Authors

**Prostate cancer screening:** A frustrating problem. Schneiderman H. 92 Aug 3.

**Take advantage of our unique services.** Williams CF. 92 Feb 3.  
**What! Not a physical finding?** Schneiderman H. 92 Jun 3.  
**You oughta be in pictures.** Williams CF. 92 Jul 2.

**Electrocardiography,** avoiding diagnostic misinterpretation. Parker BM. 92 Jul 29.

**Endocrine disorders**

diabetes mellitus and hypertension, therapeutic choices. Pedley C, Bloomfield R. 92 Sep 108.  
diabetes mellitus, nephropathy, preventive measures and therapeutic options. Markell M. 92 Jun 100.

thyroid problems, questions physicians often ask. Pont A. 92 Aug 71.

**Estrogens,** replacement therapy. Abrams J. 92 Jun 74.

**Exercise,** USPSTF recommendations. Linder MM, Motley CP, Crump WJ, Pierce PJ. 92 Mar 37.

**Fatigue,** chronic, practical guidelines for evaluation. Manu P. 92 Sep 71.  
chronic fatigue syndrome, management, what's practical and what isn't. Bryan CS. 92 Apr 33.

**Headache,** quick guide to causes other than tension and migraine. Coodley EL. 92 Mar 122.

**Hepatitis, viral,** questions physicians often ask. Mok HY. 92 Jan 65.

**Hypercholesterolemia,** USPSTF recommendations. Motley CP, Linder MM, Crump WJ, Pierce PJ. 92 May 102.

**Hyperlipidemia,** questions physicians often ask. Jones PH. 92 Nov 73.

**Hypertension,** emergencies and urgencies, treatment. Ram CVS. 92 Aug 46.

in blacks, disease characteristics and unique needs. Hildreth C. 92 Feb 109.

in diabetic patients. therapeutic choices. Pedley C, Bloomfield R. 92 Sep 108.

in renal disease. Mailloux LU. 92 Apr 48.

in the elderly. Applegate WB. 92 Oct 32.

screening, USPSTF recommendations. Motley CP, Linder MM, Crump WJ, Pierce PJ. 92 May 102.

**Incontinence, urinary,** female, evaluation and management. Campbell SC, Siegel SW. 92 Sep 45.

**Infectious disorders**

antimicrobial options, questions physicians often ask. Prichard JG. 92 Jul 86.

candidiasis, superficial and invasive. Marzouk JB, Kennedy CD. 92 Dec 71.

chronic fatigue syndrome, management, what's practical and what isn't. Bryan CS. 92 Apr 33.  
diarrhea, questions physicians often ask. Donta ST. 92 Feb 119.

hepatitis, viral, questions physicians often ask. Mok HY. 92 Jan 65.

influenza and pneumococcal pneumonia, an effective vaccination strategy. Bryan CS. 92 Sep 27.

pneumonia, community-acquired, latest antimicrobial therapy. Raju L, Khan F. 92 Jun 56.

sexually transmitted diseases, USPSTF screening recommendations. Motley CP, Linder MM, Pierce PJ, Crump WJ. 92 Nov 33.

urinary tract infection, asymptomatic, concerns in elderly. Melman A. 92 Jul 115.

urinary tract infection, differences in women and men. Fihn SD. 92 Oct 43.

**Influenza,** an effective vaccination strategy. Bryan CS. 92 Sep 27.

**Laboratory medicine,** what to do about unexpectedly elevated liver enzymes. Mok HY. 92 Dec 40.

**Liver,** enzymes, what to do when they're elevated unexpectedly. Mok HY. 92 Dec 40.

**Mammography,** screening recommendations for the busy office practice. Love RR, Davis JE. 92 Oct 23.

**Mouth,** examination, normal vs pathologic findings. Barasch A, Eisenberg E. 92 Jun 33.

**Musculoskeletal disorders**

bursitis and tendonitis, local injection therapy. Heller MB. 92 Feb 74.

osteoporosis, management, questions physicians often ask. Niewoehner CB. 92 May 131.

rheumatoid arthritis, proper use of disease-modifying agents. Grisanti JM, Wilke WS. 92 Jan 23.

**Myocardial ischemia,** when to consider angioplasty or CABG for revascularization. Nair R, Thames MD. 92 May 62.

**Neoplasms,** breast, screening mammography in your office. Love RR, Davis JE. 92 Oct 23.

breast, USPSTF recommendations for screening. Motley CP, Crump WJ, Pierce PJ. 92 Jul 59.

Zantac® 150 Tablets  
(ranitidine hydrochloride)

Zantac® 300 Tablets  
(ranitidine hydrochloride)

Zantac® Syrup  
(ranitidine hydrochloride)

The following is a brief summary only. Before prescribing, see complete prescribing information in Zantac® product labeling.

**INDICATIONS AND USAGE:** Zantac® is indicated in:

1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis).
4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated.
5. Treatment of gastroesophageal reflux disease (GERD). Symptomatic relief commonly occurs within 1 or 2 weeks after starting therapy with Zantac 150 mg b.i.d.
6. Treatment of endoscopically diagnosed erosive esophagitis. Healing of endoscopically diagnosed erosive esophagitis occurs at 4 weeks (47%), 8 weeks (71%), and 12 weeks (84%) of therapy with Zantac 150 mg q.i.d. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Zantac.

Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis.

**CONTRAINDICATIONS:** Zantac® is contraindicated for patients known to have hypersensitivity to the drug.

**PRECAUTIONS:** General: 1. Symptomatic response to Zantac® therapy does not preclude the presence of gastric malignancy. 2. Since Zantac is excreted primarily by the kidney, dosage should be adjusted in patients with impaired renal function (see DOSAGE AND ADMINISTRATION). Caution should be observed in patients with hepatic dysfunction since Zantac is metabolized in the liver.

**Laboratory Tests:** False-positive tests for urine protein with Multistix® may occur during Zantac therapy, and therefore testing with sulfosalicylic acid is recommended.

**Drug Interactions:** Although recommended doses of Zantac do not inhibit the action of cytochrome P-450 enzymes in the liver, there have been isolated reports of drug interactions that suggest that Zantac may affect the bioavailability of certain drugs by some mechanism as yet unidentified (e.g., a pH-dependent effect on absorption or a change in volume of distribution).

Increased or decreased prothrombin times have been reported during concurrent use of ranitidine and warfarin. However, in human pharmacokinetic studies with dosages of ranitidine up to 400 mg per day, no interaction occurred; ranitidine had no effect on warfarin clearance or prothrombin time. The possibility of an interaction with warfarin at dosages of ranitidine higher than 400 mg per day has not been investigated.

**Pregnancy, Lactation, and Fertility:** **Pregnancy Category B:** Reproduction studies have been performed in rats and rabbits at doses up to 160 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Zantac. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Nursing Mothers:** Zantac is secreted in human milk. Caution should be exercised when Zantac is administered to a nursing mother.

**Pediatric Use:** Safety and effectiveness in children have not been established.

**ADVERSE REACTIONS:** Headache, sometimes severe, seems to be related to Zantac administration. Constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain, and, rarely, pancreatitis have been reported. There have been rare reports of malaise, dizziness, somnolence, insomnia, vertigo, tachycardia, bradycardia, arrhythmia, block, premature ventricular beats, and arrhythmias. Rare cases of reversible mental confusion, agitation, depression, and hallucinations have been reported, predominantly in severely ill elderly patients. Rare cases of reversible blurred vision suggestive of a change in accommodation have been reported. Rare reports of reversible involuntary motor disturbances have been received.

In normal volunteers, SGPT values were increased to at least twice the pretreatment levels in 6 of 12 subjects receiving 100 mg q.i.d. intravenously for 7 days, and in 4 of 24 subjects receiving 50 mg q.i.d. intravenously for 5 days. There have been occasional reports of hepatitis, hepatocellular or hepatocellular or mixed, with or without jaundice. In such circumstances, ranitidine should be immediately discontinued. These events are usually reversible, but in exceedingly rare circumstances death has occurred.

Blood count changes (leukopenia, granulocytopenia, and thrombocytopenia) have occurred in a few patients. These were usually reversible. Rare cases of agranulocytosis, pancytopenia, sometimes with marrow hypoplasia, and aplastic anemia and occasionally rare cases of acquired immune hemolytic anemia have been reported.

Although controlled studies have shown no antiandrogenic activity, occasional cases of gynecomastia, impotence, and loss of libido have been reported in male patients receiving Zantac, but the incidence did not differ from that in the general population.

Incidents of rash, including rare cases suggestive of mild erythema multiforme, and, rarely, alopecia, have been reported, as well as rare cases of hypersensitivity reactions (e.g., urticaria, bronchospasm, fever, rash, eosinophilia), anaphylaxis, angioneurotic edema, and small increases in serum creatinine.

**OVERDOSAGE:** Information concerning possible overdose and its treatment appears in the full prescribing information.

**DOSAGE AND ADMINISTRATION:** (See complete prescribing information in Zantac® product labeling.)

**Dosage Adjustment for Patients With Impaired Renal Function:** On the basis of experience with a group of subjects with severely impaired renal function treated with Zantac, the recommended dosage in patients with a creatinine clearance less than 50 mL per minute is 150 mg or 10 mL (2 teaspoonfuls equivalent to 150 mg) of ranitidine every 24 hours. Should the patient's condition require, the frequency of dosing may be increased to every 12 hours or even further with caution. Hemodialysis reduces the level of circulating ranitidine. Ideally, the dosing schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis.

**HOW SUPPLIED:** Zantac® 150 Tablets (ranitidine HCl equivalent to 150 mg of ranitidine) are peach, film-coated, five-sided tablets embossed with "ZANTAC 150" on one side and "Glaxo" on the other. They are available in bottles of 60 (NDC 0173-0344-02) and 100 (NDC 0173-0344-09) tablets and unit dose packs of 100 (NDC 0173-0344-07) tablets.

Zantac® 300 Tablets (ranitidine HCl equivalent to 300 mg of ranitidine) are yellow, film-coated, capsule-shaped tablets embossed with "ZANTAC 300" on one side and "Glaxo" on the other. They are available in bottles of 30 (NDC 0173-0383-04) tablets and unit dose packs of 100 (NDC 0173-0383-07) tablets.

Store between 15° and 30°C (59° and 86°F) in a dry place. Protect from light. Replace cap securely after each opening.

Zantac® Syrup, a clear, peppermint-flavored liquid, contains 16.8 mg of ranitidine HCl equivalent to 15 mg of ranitidine per 5 mL in bottles of 16 fluid ounces (one pint) (NDC 0173-0383-54).

Store between 4° and 25°C (39° and 77°F). Dispense in light, light-resistant containers as defined in the USP/NF.



Zantac® 150 Tablets/Zantac® 300 Tablets  
Glaxo Pharmaceuticals, Research Triangle Park, NC 27709

Zantac® Syrup  
Manufactured for Glaxo Pharmaceuticals, Research Triangle Park, NC 27709  
by Roxane Laboratories, Inc., Columbus, OH 43216

© Copyright 1992, Glaxo Inc. All rights reserved.

Z42492P2

Printed in USA

September 1992

## Consultant 1992 Year-End Index

Guide to  
Major Subjects  
and Authors

cervical, USPSTF recommendations for screening. Motley CP, Linder MM, Crump WJ, Pierce PJ. 92 May 102.

colorectal, USPSTF recommendations for screening. Motley CP, Crump WJ, Pierce PJ. 92 Jul 59.

malignant vs benign skin lesions. Roth ME, Grant-Kels JM. 92 Apr 87.

prostate, how to screen. Trump DL. 92 Aug 27.

prostate, new modalities to aid in early detection. Blath RA. 92 Dec 23.

skin signs of systemic cancer. Wooldridge WE. 92 Feb 31.

**Nutrition, USPSTF recommendations.** Linder MM, Motley CP, Crump WJ, Pierce PJ. 92 Mar 37.

**Osteoporosis, management, questions physicians often ask.** Niewoehner CB. 92 May 131.

### Photoclinic

92 Jan 77. Depigmentation following corticosteroid tendon injection, Stevens-Johnson syndrome, 'nursing bottle' syndrome, teeth stained by minocycline.

92 Feb 93. Erythema ab igne, staphylococcal scalded skin syndrome, subconjunctival hemorrhage associated with pertussis, scarring alopecia secondary to SLE.

92 Mar 107. Cutis verticis gyrata, neurofibromas, embryonated *Enterobius vermicularis*, dermal vasculitis of systemic lupus erythematosus, dermatographism, Beau's lines.

92 Apr 135. Bullous myringitis, tophi of gout, polychlorinated biphenyl dermatitis, acral fibrokeratoma, plant contact dermatitis, leukoplakia of the tongue.

92 May 121. Aphthous ulcers, cutaneous metastasis of prostate adenocarcinoma, end-stage rheumatoid arthritis, secondary syphilis: 'the great imitator.'

92 Jun 127. Tinea incognita, ulcerating basal cell carcinoma, exfoliative erythroderma, Bell's palsy, myotonic dystrophy, rickets in young child.

92 Jul 125. Allergic angioedema, bullous pemphigoid, granuloma pyogenicum, contact sensitization following herpes zoster, iliac artery aneurysm, cutaneous horn.

92 Aug 94. Goiter in postpartum thyroiditis, dermatitis from old sandal, Ehlers-Danlos syndrome,

nexus of Ota, clinical evidence of nail-patella syndrome.

92 Sep 99. Ventricular aneurysm, lepromatous leprosy, digital mucous cyst, hirsutism, malignant melanoma.

92 Oct 83. Onychogryphosis ('Ram's horn' nails), cutaneous T-cell tumor in an HIV-positive patient, pitted keratolysis, Zoon's balanitis, difficulty in interpreting radiographs in facial trauma.

92 Nov 79. Torus palatinus, angiodysplasia of the cecum, acral erythema from chemotherapy, hemangioblastoma, berloque dermatitis.

92 Dec 81. Spontaneous pneumothorax, vasculopathy of primary antiphospholipid antibody syndrome, infection with atypical mycobacterial organism.

**Physical examination, of the mouth, normal vs pathologic findings.**

Barasch A, Eisenberg E. 92 Jun 33.

**Pneumonia, community-acquired, latest antimicrobial therapy.** Raju L, Khan F. 92 Jun 56.

### Practical Pointers

Abdominal pain and ketoacidosis. 92 Sep 41.

Achilles tendon reflex reinforcement. 92 Nov 46.

Add color to patients' files. 92 Mar 100.

Advice that can reduce knee injury rates. 92 Mar 100.

Air filters for allergic rhinitis. 92 Jan 62.

Are you getting false BP readings? 92 Nov 46.

Basic serologic tests for suspected arthritis or SLE. 92 Sep 41.

Bran need not be a penitential experience. 92 May 37.

Break the itch-scratch cycle. 92 Dec 38.

Breast map relieves anxiety. 92 Sep 41.

Carry tetanus reminder on driver's license. 92 May 37.

Caveat regarding frontal sinusitis. 92 Feb 73.

Clue to diaphragmatic weakness. 92 Feb 73.

Complex medical history needn't dampen wanderlust. 92 Apr 42.

CONSULTANT redux! 92 Aug 37.

Convenient cold pack. 92 Feb 73.

Convenient notification of lab results. 92 Jun 65.

**Consultant 1992  
Year-End Index**

Guide to  
Major Subjects  
and Authors

Coping with new terminology. 92 Apr 42.  
Cost-effective wound drape. 92 Apr 42.  
Criterion for treating hypertension. 92 Mar 100.  
Detecting occipital neuralgia. 92 Jun 65.  
Diabetes can mask symptoms of acute cholecystitis. 92 Feb 73.  
Differentiating clue to meningitis. 92 Mar 100.  
Don't hold your patient's breath! 92 Nov 46.  
Drop a card. 92 Apr 42.  
Dry stool sampling. 92 Jul 69.  
Easier ophthalmoscopy. 92 Mar 100.  
Easier urine collection from diapers. 92 Nov 46.  
Easy test for vesicovaginal fistula. 92 Apr 42.  
Eliminating stethoscope noise artifact. 92 Aug 37.  
Encourage artwork to keep kids quiet. 92 Nov 46.  
For a walkable walking cast. 92 Jun 65.  
For heavyweights only. 92 Apr 42.  
For more toothsome travel. 92 Apr 42.  
'Four times before.' 92 May 37.  
Frame the color plates. 92 Sep 41.  
FUO sources in elderly patients. 92 Feb 73.  
Further improvements in treating aphthous ulcers. 92 Oct 28.  
Gallstones during pregnancy. 92 May 37.  
Get a hand 'close-up' for diagnostic accuracy. 92 Sep 41.  
Getting the message across to younger smokers. 92 Jul 69.  
Good for the skin but not for the culture vial! 92 Oct 28.  
Handy test for testicular self-exam. 92 Jan 62.  
Have you a game plan for office emergencies? 92 Mar 100.  
Have you obtained an *acceptable* sputum sample? 92 Feb 73.  
Helpful hospital discharge letter. 92 May 37.  
Honoring patients with hospital donation. 92 Feb 73.  
Ice the nasogastric tube. 92 Aug 37.  
Identifying oral ulcers of TB. 92 May 37.  
Improve grip with benzoin. 92 Sep 41.  
Improved access to central line placement. 92 Jul 69.  
Improved technique for treating aphthous ulcers. 92 Jul 69.

Indian grip reduces gagging. 92 Dec 38.  
It's in the bag. 92 Sep 41.  
Just say no! 92 Aug 37.  
Kinder, gentler cast removal. 92 Aug 37.  
Look under dentures. 92 Sep 41.  
Lubricate syringe to prevent sticking. 92 Oct 28.  
Multipurpose office form is a boon. 92 Jul 69.  
Needle as aid in excision. 92 Aug 37; 92 Oct 28.  
Nose spray in due season. 92 May 37.  
Observe first, even though bleeding is alarming. 92 Aug 37.  
Ophthalmoscopy made even easier. 92 Aug 37.  
Overcoming patients' reluctance to receive INH. 92 Nov 46.  
Palpate for S<sub>3</sub>. 92 Jun 65.  
Passing a nasogastric tube. 92 Apr 42.  
Phlebitis test. 92 Sep 41.  
Photocopy those warts. 92 Apr 42.  
Pill swallowing. 92 Apr 42.  
Pillow aids in palpation. 92 Dec 38.  
Practice the pediatric hold. 92 Nov 46.  
Preventing side effects of aerosols. 92 Jun 65.  
Preview prepares parents for problem. 92 Jul 69.  
Quick check for depression. 92 Apr 42.  
Reaction to medication is clue to diagnosis. 92 Aug 37.  
Recipe for hot compresses. 92 Nov 46.  
Remove the sting, but maintain anesthesia. 92 Feb 73.  
Safe disposal of soft infectious waste. 92 Jun 65.  
Safe slide transportation. 92 Jun 65.  
Score influences clinical decisions in pharyngitis. 92 Sep 41.  
Serve up electrolytes for dessert. 92 Dec 38.  
Shoulder pain—not from the shoulder. 92 Apr 42.  
Significance of ESR in evaluation. 92 Oct 28.  
Simple nail calculation. 92 May 37.  
Simplifying hospitalization documentation. 92 Jul 69.  
Sitting in the garden. 92 Apr 42.  
Small squirt sans scrubbing. 92 Aug 37.  
Soapless cleanser, skin soother. 92 Sep 41.  
Speed wound healing with different dressing. 92 Jan 62.  
Speedy sting treatment. 92 Aug 37.  
Stabilizing a rolling vein. 92 Apr 42.  
Substitution for bronchoscopy. 92 May 37.

Suction tubing prevents pressure necrosis. 92 Apr 42.  
Surge of skin lesions sounds an alarm. 92 Dec 38.  
Surgical mask as ear covering. 92 Jul 69.  
Tetracycline for aphthous ulcers. 92 Feb 73.  
To assess efficacy of nitroglycerin tablets. 92 Nov 46.  
Touch a roaring cast saw. 92 Nov 46.  
Toy tames tots' tears. 92 May 37.  
Try a gauze drape. 92 Dec 38.  
Use the 'ophthalmo-otoscope.' 92 Nov 46.  
Visual symptoms may signal digitalis toxicity. 92 Oct 28.  
When hypercaloric replacement is needed. 92 May 37.  
X marks the spot. 92 Apr 42.  
**Pregnancy**, respiratory changes, normal physiology vs true disease. Thappa V, Sicilian L. 92 Jun 136.  
**Preventive medicine**, dental screening, USPSTF screening recommendations. Motley CP, Linder MM, Pierce PJ, Crump WJ. 92 Nov 33.  
drug use and injury prevention, USPSTF recommendations. Linder MM, Crump WJ, Pierce PJ. 92 Apr 57.  
exercise and nutrition, USPSTF recommendations. Linder MM, Motley CP, Crump WJ, Pierce PJ. 92 Mar 37.  
mammography strategy for busy office practice. Love RR, Davis JE. 92 Oct 23.  
screening for colorectal and breast cancer, USPSTF recommendations. Motley CP, Crump WJ, Pierce PJ. 92 Jul 59.  
screening for hypercholesterolemia, hypertension, and cervical cancer, USPSTF recommendations. Motley CP, Linder MM, Crump WJ, Pierce PJ. 92 May 102.  
screening for sexually transmitted diseases, USPSTF recommendations. Motley CP, Linder MM, Pierce PJ, Crump WJ. 92 Nov 33.  
**Prostate**, cancer, how to screen for. Trump DL. 92 Aug 27.  
cancer, new modalities to aid in early detection. Blath RA. 92 Dec 23.  
**Pulmonary disorders**  
asthma, management. Speir WA, Callahan LA. 92 Mar 67.  
pneumonia, community-acquired, latest antimicrobial therapy. Raju L, Khan F. 92 Jun 56.



**Consultant 1992  
Year-End Index**

Guide to  
Major Subjects  
and Authors

- respiratory changes in pregnancy, normal physiology vs true disease. Thappa V, Sicilian L. 92 Jun 136.
- status asthmaticus, aggressive management. Harman EM. 92 Jan 54.
- unusual presentations of asthma, part 1. Reynolds HY, Maxwell SL. 92 Feb 48.
- unusual presentations of asthma, part 2. Reynolds HY, Maxwell SL. 92 Apr 79.
- Questions Physicians Often Ask**
- asthma, management. Speir WA, Callahan LA. 92 Mar 67.
- diarrhea. Donta ST. 92 Feb 119.
- hepatitis, viral. Mok HY. 92 Jan 65.
- osteoporosis, management. Niewoehner CB. 92 May 131.
- thyroid disorders. Pont A. 92 Aug 71.
- Sexually transmitted diseases**, USPSTF screening recommendations. Motley CP, Linder MM, Pierce PJ, Crump WJ. 92 Nov 33.
- Status asthmaticus**, early intervention and aggressive management. Harman EM. 92 Jan 54.
- Tendonitis**, local injection therapy. Heller MB. 92 Feb 74.
- Thyroid**, disorders, questions physicians often ask. Pont A. 92 Aug 71.
- Urinary tract**, incontinence, female, evaluation and management. Campbell SC, Siegel SW. 92 Sep 45.
- infection, asymptomatic, concerns in elderly. Melman A. 92 Jul 115.
- infection, differences in women and men. Fihn SD. 92 Oct 43.
- Vaccination**, effective strategy for influenza and pneumococcal pneumonia. Bryan CS. 92 Sep 27.
- What's Your Diagnosis?**
- Acute anterolateral wall myocardial infarction. 92 Aug 65.
- Acute inferoposterolateral myocardial infarction. 92 Nov 59.
- Addisonian pigmentation. 92 Dec 61.
- Angular cheilitis. 92 Oct 69.
- Atheromatous embolism. 92 Oct 73.
- Blood blisters of thrombocytopenia. 92 Apr 131.
- Digital pulp space infection. 92 Jan 51.
- Disseminated histoplasmosis. 92 Oct 79.
- Fissured tongue. 92 Jun 89.
- Gowers' sign. 92 Nov 49.
- Hereditary hemorrhagic telangiectasia. 92 Aug 67.
- Herpes infection of hard palate. 92 May 87.
- Holocaust camp survivor. 92 Jun 83.
- Infected thyroglossal duct cyst. 92 Jul 111.
- Kaposi's sarcoma of the toe. 92 Jul 105.
- Leser-Trélat sign in a nonagenarian. 92 Sep 85.
- Macroglossia due to acromegaly. 92 Feb 69.
- Measles (rubeola), with Koplik's spots. 92 Mar 93.
- Metacarpophalangeal joint arthritis. 92 May 91.
- Pigmented villonodular synovitis. 92 May 79.
- Posterior wall myocardial infarction. 92 Jun 95.
- Ptoisis due to cranial nerve III palsy. 92 Mar 83.
- Ram's horn nails. 92 Aug 61.
- Red lunula. 92 Nov 53.
- Rheumatoid arthritis. 92 Feb 63.
- Rosacea with rhinophyma. 92 Jan 45.
- Sarcoidosis. 92 Jul 95.
- Severe airway obstruction. 92 Apr 125.
- Sickle cell anemia. 92 Sep 81.
- Squamous carcinoma of the vulva. 92 Mar 87.
- Suppurative thrombophlebitis. 92 Jan 41.
- Testicular cancer. 92 Sep 89.
- Transverse white lines (Mees') of the fingernails. 92 Dec 51.
- AUTHORS:**
- Abrams, Jerome** estrogen-replacement therapy. 92 Jun 74.
- Addison, Wayne O** acute anterolateral wall myocardial infarction (What's Your Diagnosis?), 92 Aug 65; acute inferoposterolateral myocardial infarction (What's Your Diagnosis?), 92 Nov 59.
- Applegate, William B** new guidelines for managing hypertension in the elderly. 92 Oct 32.
- Auber, Andrew E** pigmented villonodular synovitis (What's Your Diagnosis?), 92 May 79.
- Barrasch, Andrei** oral examination. 92 Jun 33.
- Blaisdell, F William** suppurative thrombophlebitis (What's Your Diagnosis?), 92 Jan 41.
- Blath, Richard A** new modalities to aid in early diagnosis of prostate cancer. 92 Dec 23.
- Bloomfield, Robert** hypertension in diabetes. 92 Sep 108.
- Brofeldt, Bo Tomas** suppurative thrombophlebitis (What's Your Diagnosis?), 92 Jan 41.
- Bryan, Charles S** practical management of chronic fatigue syndrome. 92 Apr 33; influenza and pneumonia vaccination strategy. 92 Sep 27; disseminated histoplasmosis (What's Your Diagnosis?), 92 Oct 79.
- Callahan, Leigh Ann** asthma management (Questions Physicians Often Ask). 92 Mar 67.
- Campbell, Steven C** female urinary incontinence. 92 Sep 45.
- Cone, JB** primary care approach to burn injuries. 92 May 29.
- Coodley, Eugene I** quick guide to causes of headache other than tension and migraine. 92 Mar 122.
- Crump, William J** USPSTF recommendations (adults) for exercise and nutrition. 92 Mar 37; for screening for drug use and injury. 92 Apr 57; screening for hypercholesterolemia, hypertension, and cervical cancer. 92 May 102; screening for colorectal and breast cancers. 92 Jul 59; dental and STD screening. 92 Nov 33.
- Davis, James E** screening mammography in the busy office practice. 92 Oct 23.
- Donta, Sam T** infectious diarrhea (Questions Physicians Often Ask). 92 Feb 119.
- Eisenberg, Ellen** oral examination. 92 Jun 33.
- Fihn, Stephan D** UTI management in women and men. 92 Oct 43.
- Grant-Kels, Jane M** malignant vs benign skin lesions. 92 Apr 87.
- Grisanti, Joseph M** disease-modifying agents in rheumatoid arthritis. 92 Jan 23.
- Harman, Eloise M** aggressive management for status asthmaticus. 92 Jan 54.
- Heller, Michael B** local injection therapy for bursitis/tendonitis. 92 Feb 74.
- Hildreth, Carolyn** hypertension in blacks. 92 Feb 109.
- Jones, Peter H** hyperlipidemia (Questions Physicians Often Ask). 92 Nov 73.
- Katz, Arnold M** posterior wall myocardial infarction (What's Your Diagnosis?), 92 Jun 95; acute anterolateral wall myocardial infarction (What's Your Diagnosis?), 92 Aug 65; acute

**Consultant 1992  
Year-End Index**

Guide to  
Major Subjects  
and Authors

- inferoposterolateral myocardial infarction (What's Your Diagnosis?), 92 Nov 59.
- Kennedy, Charles D** superficial and invasive candidiasis, 92 Dec 71.
- Kerins, Gerry** Leser-Trélat sign in a nonagenarian (What's Your Diagnosis?), 92 Sep 85.
- Khan, Fareque** community-acquired pneumonia, 92 Jun 56.
- Kramer, Donald I** office use of local anesthetics, 92 Nov 25.
- Linder, Michael M** USPSTF recommendations (adults) for exercise and nutrition, 92 Mar 37; for screening for drug use and injury, 92 Apr 57; screening for hypercholesterolemia, hypertension, and cervical cancer, 92 May 102; dental and STD screening, 92 Nov 33.
- Love, Richard R** screening mammography in the busy office practice, 92 Oct 23.
- Mailloix, Lionel U** hypertension in renal disease, 92 Apr 48.
- Manu, Peter** guidelines for evaluating chronic fatigue, 92 Sep 71.
- Markell, Mariann** diabetic nephropathy, 92 Jun 100.
- Marzouk, Joseph B** superficial and invasive candidiasis, 92 Dec 71.
- Maxwell, Steven I** unusual presentations of asthma, part 1, 92 Feb 48; part 2, 92 Apr 79.
- Melman, Arnold** asymptomatic UTI in the elderly, 92 Jul 115.
- Mikaru, Fidelis O** posterior wall myocardial infarction (What's Your Diagnosis?), 92 Jun 95.
- Mok, Henry Y** viral hepatitis (Questions Physicians Often Ask), 92 Jan 65; what to do about unexpectedly elevated liver enzymes, 92 Dec 40.
- Morganroth, Joel** oral therapy for ventricular arrhythmias, 92 Mar 113.
- Motley, Carol P** USPSTF recommendations (adults) for exercise and nutrition, 92 Mar 37; screening for hypercholesterolemia, hypertension, and cervical cancer, 92 May 102; screening for colorectal and breast cancers, 92 Jul 59; dental and STD screening, 92 Nov 33.
- Murphy, Dale P** Breast cancer: organizing the fight at the primary care level (Ed Comm), 92 Oct 3.
- Nair, Ravi** angioplasty or CABG for myocardial revascularization, 92 May 62.
- Niewoehner, Catherine B** osteoporosis management (Questions Physicians Often Ask), 92 May 131.
- Noyes, Lisa** transverse white (Mees') lines of the fingernails (What's Your Diagnosis?), 92 Dec 51.
- Parker, Brent M** avoiding diagnostic misinterpretation on ECGs, 92 Jul 29.
- Pedley, Carolyn** hypertension in diabetes, 92 Sep 108.
- Pierre, Peggy J** USPSTF recommendations (adults) for exercise and nutrition, 92 Mar 37; for screening for drug use and injury, 92 Apr 57; screening for hypercholesterolemia, hypertension, and cervical cancer, 92 May 102; screening for colorectal and breast cancers, 92 Jul 59; dental and STD screening, 92 Nov 33.
- Pont, Allan** thyroid problems (Questions Physicians Often Ask), 92 Aug 71.
- Prichard, John G** antimicrobial options (Questions Physicians Often Ask), 92 Jul 86.
- Raju, Linga** community-acquired pneumonia, 92 Jun 56.
- Ram, C Venkata S** treatment for hypertensive emergencies and urgencies, 92 Aug 46.
- Reynolds, Herbert Y** unusual presentations of asthma, part 1, 92 Feb 48; part 2, 92 Apr 79.
- Roth, Monique E** malignant vs benign skin lesions, 92 Apr 87.
- Rothe, Marti Jill** drug rashes, 92 May 38.
- Schneiderman, Henry** What! Not a physical finding? (Ed Comm), 92 Jun 3; Prostate cancer screening: a frustrating problem (Ed Comm), 92 Aug 3; What's Your Diagnosis? 92 Jan 41; 92 Jan 45; 92 Jan 51; 92 Feb 63; 92 Feb 69; 92 Mar 83; 92 Mar 87; 92 Mar 93; 92 Apr 125; 92 Apr 131; 92 May 79; 92 May 87; 92 May 91; 92 Jun 83; 92 Jun 89; 92 Jul 95; 92 Jul 105; 92 Jul 111; 92 Aug 61; 92 Aug 67; 92 Sep 81; 92 Sep 85; 92 Sep 89; 92 Oct 69; 92 Oct 73; 92 Oct 79; 92 Nov 49; 92 Nov 53; 92 Dec 51; 92 Dec 61.
- Shahady, Edward J** Chronic fatigue syndrome (Ed Comm), 92 Apr 3; Prepare for the coming flu season (Ed Comm), 92 Sep 2.
- Shanley, Dean J** pigmented villonodular synovitis (What's Your Diagnosis?), 92 May 79.
- Sherman, Scott C** office use of local anesthetics, 92 Nov 25.
- Scillian, Leonard** respiratory changes in pregnancy, 92 Jun 136.
- Siegel, Steven W** female urinary incontinence, 92 Sep 45.
- Speir, William A** asthma management (Questions Physicians Often Ask), 92 Mar 67.
- Thames, Marc D** angioplasty or CABG for myocardial revascularization, 92 May 62.
- Thappa, Vivek** respiratory changes in pregnancy, 92 Jun 136.
- Trump, Donald L** screening for prostate cancer, 92 Aug 27.
- Wilke, William S** disease-modifying agents in rheumatoid arthritis, 92 Jan 23.
- Williams, Charles F** Matching our editorial format to your needs (Ed Comm), 92 Jan 2; Take advantage of our unique services (Ed Comm), 92 Feb 3; Access to top experts—yours for the asking (Ed Comm), 92 May 2; You oughta be in pictures (Ed Comm), 92 Jul 2; Information you—the doctor—ordered, 92 Nov 3.
- Wooldridge, Wilfred E** dermatologic signs of systemic cancer, 92 Feb 31; sarcoidosis (What's Your Diagnosis?), 92 Jul 95.

